Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions
Keywords: Asthma; roflumilast; phosphodiesterase type 4; allergen provocation; inflammation; late phase; AHR; Airway hyperresponsiveness; AUC; Area under the curve; cAMP; Cyclic adenosine monophosphate; COPD; Chronic obstructive pulmonary disease; EAR; Early asthma